President Donald Trump has the chance to protect patients from the worst consequences of these price controls.
Perhaps his administration can find a way to pause the IRA’s latest round of price controls before they do any more damage. But what’s really required is full-scale repeal by Congress.
On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act.
Among them is the blockbuster semaglutide, a prescription medication sold by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus for the treatment of Type 2 diabetes and obesity. The IRA required the federal government to publish the list of 15 drugs before Feb. 1, and so the Biden administration decided to act on its way out the door.
The makers of those 15 drugs have until Feb. 28 to decide whether to enter into negotiations with the government.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Patients Pay Dearly for Biden’s Pricing Mess
Sally C. Pipes
President Donald Trump has the chance to protect patients from the worst consequences of these price controls.
Perhaps his administration can find a way to pause the IRA’s latest round of price controls before they do any more damage. But what’s really required is full-scale repeal by Congress.
On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act.
Among them is the blockbuster semaglutide, a prescription medication sold by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus for the treatment of Type 2 diabetes and obesity. The IRA required the federal government to publish the list of 15 drugs before Feb. 1, and so the Biden administration decided to act on its way out the door.
The makers of those 15 drugs have until Feb. 28 to decide whether to enter into negotiations with the government.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.